Urology clinical trials
Landmark trials to watch, new trials and recent readouts in urology and GU oncology.
Recent readouts
- Opioid-free anesthesia shows no significant benefit over opioid-based technique in prostatectomy
In a 57-patient randomized trial, opioid-free anesthesia did not significantly reduce 24-hour postoperative oxycodone consumption or pain scores compared with remifentanil-based anesthesia during laparoscopic radical prostatectomy.
- Adding trilaciclib to chemo-immunotherapy did not improve PFS in advanced urothelial cancer
In a randomized phase 2 trial of 92 patients with advanced urothelial carcinoma, adding trilaciclib to platinum chemotherapy plus avelumab maintenance showed modest myeloprotective effects but no improvement in progression-free survival (6.6 vs 6.1 months overall, HR 0.94).
- Cretostimogene reduces NMIBC recurrence risk by 68% in Phase 3 PIVOT-006, company reports
CG Oncology announced topline results from its Phase 3 PIVOT-006 trial, reporting that cretostimogene reduced recurrence risk by 68% in NMIBC patients, with no patients discontinuing treatment due to related side effects. Full data and statistical details have not yet been disclosed.
- FDA approves durvalumab with enfortumab vedotin for muscle-invasive bladder cancer
FDA approved the perioperative combination of durvalumab (an immune checkpoint inhibitor) and enfortumab vedotin-ejfv for muscle-invasive bladder cancer.
- ANKTIVA plus BCG meets primary endpoint in randomized BCG-naive NMIBC trial
The randomized QUILT-2.005 trial of ANKTIVA (nogapendekin alfa inbakicept) added to BCG met its primary endpoint in patients with BCG-naive non-muscle invasive bladder cancer, according to a company announcement; detailed results were not reported.
- CAPItello-281: overall survival results reported for capivasertib in PTEN-deficient mHSPC
Coverage discusses overall survival results from the CAPItello-281 phase 3 trial testing capivasertib in PTEN-deficient metastatic hormone-sensitive prostate cancer, but the specific survival data are not detailed in this item.
- PROTEUS substudy: perioperative apalutamide plus ADT improves event-free survival before RP
In a randomized substudy of high-risk localized/locally advanced prostate cancer patients undergoing radical prostatectomy, adding 1-year perioperative apalutamide plus ADT improved event-free survival versus surgery alone (median not reached vs 19.1 months; 3-year EFS 63% vs 41%).
- RCT: Prehabilitation before robotic prostatectomy improves early quality of life and continence
In a single-center RCT of 95 men undergoing robotic-assisted radical prostatectomy, a 4-week multimodal prehabilitation program (physical, pelvic floor, nutrition, psychological) improved global quality of life and continence at 1 month. The global quality-of-life benefit attenuated by 6 months, but continence and some other HRQoL and mental health improvements were maintained through 6 months.
- BART phase 3: adjuvant pelvic radiotherapy after cystectomy improves locoregional control in high-risk MIBC
In 153 patients with high-risk muscle-invasive bladder cancer after radical cystectomy and chemotherapy, adjuvant pelvic radiotherapy improved 2-year locoregional failure-free survival (87.1% vs 76.0%; HR 0.43). Disease-free and overall survival differences were not statistically significant.
- Adding belzutifan or quavonlimab to pembrolizumab-lenvatinib fails to improve PFS or OS in RCC
In the phase 3 LITESPARK-012 trial, adding belzutifan or quavonlimab/pembrolizumab to pembrolizumab plus lenvatinib did not improve PFS or OS versus pembrolizumab-lenvatinib alone in first-line advanced clear-cell RCC.
- Belzutifan-lenvatinib keeps PFS and response edge over cabozantinib in RCC, OS not significant
Final LITESPARK-011 analysis in previously treated advanced clear-cell RCC shows belzutifan plus lenvatinib maintained PFS (HR 0.74) and response rate benefits over cabozantinib, but mature OS (HR 0.85) did not cross the prespecified significance boundary.
- Durvalumab (Imfinzi) plus enfortumab vedotin (Padcev) cuts death risk 42% in bladder cancer trial
A trial of durvalumab (Imfinzi) plus enfortumab vedotin (Padcev) reported a 42% reduction in death risk in bladder cancer, though the report notes it trails the pembrolizumab (Keytruda)-based combination.
- Xencor selects phase 3 dose for XmAb819 after 45.5% response rate in RCC
XmAb819, a bispecific antibody, showed a 45.5% objective response rate in a kidney cancer trial, prompting selection of a phase 3 dose.
- LITESPARK-011 final analysis: belzutifan plus lenvatinib keeps its PFS edge over cabozantinib, but OS is not significant
In 747 patients with advanced RCC after anti-PD-(L)1 therapy (median follow-up 38.8 months), belzutifan plus lenvatinib versus cabozantinib gave median PFS of 14.8 vs 10.8 months (HR 0.74) and ORR of 53.1% vs 40.2%. Median OS was 33.7 vs 28.6 months (HR 0.85, 95% CI 0.70 to 1.03), which did not cross the prespecified significance boundary. Grade 3 or higher adverse events were 85.4% vs 83.0%.
- ENZARAD: Enzalutamide added no MFS or OS benefit over older antiandrogen with ADT/RT
In this phase 3 trial of 802 men with high-risk localized/locally advanced prostate cancer, adding enzalutamide for 24 months to ADT and radiotherapy did not significantly improve 8-year metastasis-free survival versus an older nonsteroidal antiandrogen given for 6 months (74% vs 72%, HR 0.88, P=0.34).
- J&J reports 75% tumor response rate with novel RIPTAC molecule JNJ-6143 in mCRPC
Johnson & Johnson reported a 75% tumor response rate for JNJ-6143, a first-in-class RIPTAC molecule, in an early-phase study in advanced prostate cancer.
- LITESPARK-012: adding belzutifan or quavonlimab to pembrolizumab plus lenvatinib does not improve first-line RCC outcomes
In first-line advanced RCC, neither pembrolizumab plus lenvatinib plus belzutifan nor MK-1308A (quavonlimab plus pembrolizumab) plus lenvatinib beat pembrolizumab plus lenvatinib. Median PFS was 20.8 and 20.7 vs 23.7 months (HR 1.08 and 1.07), and OS HRs were 1.04 and 1.12. ORR was 69.1% and 69.0% vs 76.3%.
- Updated CAPItello-281 analysis shows OS benefit with capivasertib-abiraterone in PTEN-deficient mHSPC
In an ad hoc, non-prespecified descriptive analysis of the phase 3 CAPItello-281 trial at 42% survival data maturity (median follow-up 39 months), capivasertib plus abiraterone showed an overall survival benefit over placebo plus abiraterone in PTEN-deficient de novo mHSPC (median 57.4 vs 46.5 months, HR 0.82, 95% CI 0.68-0.99, P=0.044), consistent with the updated radiographic progression-free survival benefit (HR…
- KEYNOTE-866: Perioperative pembrolizumab did not significantly improve event-free survival in cisplatin-eligible MIBC
In this phase 3 trial of 907 cisplatin-eligible MIBC patients, adding perioperative pembrolizumab to neoadjuvant cisplatin-gemcitabine did not significantly improve 5-year event-free survival (63.5% vs 61.9%, HR 0.88) despite a higher pathologic complete response rate (44.4% vs 35.8%).
- Final CA017-078 results: perioperative nivolumab plus chemo did not improve event-free survival in MIBC
In this phase 3 trial of 653 patients with resectable MIBC, neoadjuvant nivolumab plus gemcitabine-cisplatin followed by adjuvant nivolumab improved pathologic complete response (39.1% vs 29.6%) but did not improve event-free survival compared to chemotherapy alone (HR 0.94) at a median follow-up of 54.5 months.
- VOLGA: perioperative durvalumab plus enfortumab vedotin improves EFS and OS in cisplatin-ineligible MIBC
In 695 patients with MIBC who were cisplatin-ineligible or declined cisplatin (median follow-up 23 months), perioperative durvalumab plus neoadjuvant enfortumab vedotin improved event-free survival versus upfront cystectomy (HR 0.51, 95% CI 0.38 to 0.67; 24-month EFS 64% vs 45%) and overall survival (HR 0.58; 24-month OS 78% vs 69%). pCR was 45% vs 10%. Adding tremelimumab improved EFS (HR 0.61) but not OS at this interim analysis.
- PEACE-1 long-term update: abiraterone added to ADT plus docetaxel extends survival in de novo mCSPC
At a median follow-up of 7.7 years, in the 710 men treated with ADT plus docetaxel, adding abiraterone improved overall survival (HR 0.68, 95% CI 0.56 to 0.82; median 6.2 vs 4.4 years). In high-volume disease, median OS was 4.6 vs 3.5 years (HR 0.68) and 38% vs 20% were alive at 8 years. In low-volume disease, median OS was 7.8 vs 6.2 years (HR 0.74, 95% CI 0.52 to 1.05), not significant on its own.
- POTOMAC: durvalumab plus BCG improves DFS in papillary-only, BCG-naive high-risk NMIBC
In a prespecified subgroup of 437 patients with papillary-only high-risk NMIBC (median follow-up 60.7 months), durvalumab with BCG induction and maintenance reduced disease-free survival events versus BCG alone (HR 0.56, 95% CI 0.37 to 0.84; 17% vs 30% with events). DFS at 48 months was 84% vs 74%. In the post hoc T1 subset, the HR was 0.48.
- Darolutamide plus ADT and radiation cuts metastasis or death risk in high-risk prostate cancer
In the DASL-HiCaP (ANZUP1801) trial, adding darolutamide to ADT and definitive or salvage radiotherapy reduced the risk of metastasis or death by 58% compared to ADT and radiotherapy alone in patients with localized very high-risk prostate cancer. This is a randomized phase 3 result in a population selected for high recurrence risk.
- ENERGIZE (CA017-078): perioperative nivolumab plus gemcitabine-cisplatin misses both co-primary endpoints in MIBC
In 653 patients with resectable MIBC (median follow-up 54.5 months), neoadjuvant nivolumab plus gemcitabine-cisplatin, cystectomy and 9 cycles of adjuvant nivolumab did not improve event-free survival versus gemcitabine-cisplatin and cystectomy (HR 0.94, 95.74% CI 0.71 to 1.25; P=0.67). Pathologic complete response was 39.1% vs 29.6%, not significant. OS was immature (HR 0.88). Grade 3 or higher treatment-related adverse events were 45.9% vs 49.5%.
- KEYNOTE-866: perioperative pembrolizumab with cisplatin-gemcitabine does not improve EFS in cisplatin-eligible MIBC
In 907 cisplatin-eligible patients with MIBC (median follow-up 60.9 months), adding perioperative pembrolizumab to neoadjuvant cisplatin-gemcitabine did not significantly improve event-free survival (HR 0.88, 95% CI 0.71 to 1.10; 60-month EFS 63.5% vs 61.9%). pCR rose to 44.4% vs 35.8%, but OS was identical (HR 1.00). Grade 3 to 5 adverse events were 80.2% vs 75.1%.
- Randomized phase 2: talazoparib-enzalutamide met PSA goal but showed no clear benefit over enzalutamide alone
In 54 men with high-volume mHNPC unselected for HRR mutations, talazoparib plus enzalutamide met its prespecified single-arm PSA response threshold (73% vs prespecified goal, P<0.001). The exploratory comparison to enzalutamide alone (64.7%) was not significant (P=0.54). Combination therapy caused more grade 3+ toxicity (68% vs 35%) including two fatal myeloid neoplasms.
- Phase 2 trial: neoadjuvant radiation before IVC thrombectomy for RCC appears feasible
Single-center prospective phase 2 nonrandomized trial gave neoadjuvant stereotactic ablative radiotherapy to IVC tumor thrombus before nephrectomy/thrombectomy in 23 patients with RCC; 22 completed surgery and 21 were evaluable for the primary 1-year recurrence-free survival endpoint, compared with a prespecified historical surgery-alone benchmark of 55.7%.
- Focal salvage HDR brachytherapy shows low acute toxicity in phase I/II trial for radiorecurrent prostate cancer
In the 62-patient F-SHARP phase I/II trial of dose-escalated focal salvage HDR brachytherapy after prior radiotherapy, no acute grade 3 toxicity occurred (2 patients had late grade 3 toxicity) and 3-year biochemical PFS was 62.7%. Among 31 patients with genomic classifier data, all 4 with scores above 0.85 experienced recurrence, suggesting a possible biomarker for risk stratification.
- ARASENS substudy: darolutamide plus docetaxel shows no clinically relevant PK drug interaction
In this secondary dosing/safety/PK analysis of the phase 3 ARASENS trial, 87.6% of darolutamide patients and 85.5% of placebo patients completed 6 docetaxel cycles. Docetaxel plasma concentrations were similar with and without darolutamide, and darolutamide exposure was only 10% lower with docetaxel, neither considered clinically relevant.
- Extended LUNAR follow-up: neoadjuvant 177Lu-PNT2002 before SBRT sustains PFS gain
In the phase 2 LUNAR trial of oligorecurrent hormone-sensitive prostate cancer, adding two cycles of neoadjuvant 177Lu-PNT2002 before SBRT improved median PFS (17.6 vs 7.4 months, HR 0.38) and hormonal therapy-free survival versus SBRT alone at 31.9 months follow-up.
- PSMA-guided radiotherapy intensification shows modest FFS benefit at 5 years
In a phase 2 randomized trial (n=253), PSMA-PET-guided radiotherapy intensification to all detected sites did not significantly improve failure-free survival versus standard radiotherapy (66% vs 62% at 5 years), though freedom from biochemical progression favored the PSMA-guided arm.
- SAKK 06/19: adding intravesical BCG to perioperative chemoimmunotherapy in MIBC
Primary analysis of the single-arm, open-label phase II SAKK 06/19 trial, which added intravesical recombinant BCG to perioperative chemoimmunotherapy in high-risk muscle-invasive bladder cancer.
- PACE-A trial: sexual function outcomes compared between prostatectomy and SBRT
Long-term sexual function results from the multicenter randomized PACE-A trial comparing radical prostatectomy versus SBRT for early localized prostate cancer, presented at ASTRO 2026.
- PACE-A: SBRT and prostatectomy show similar long-term cancer control
Long-term follow-up of the PACE-A randomized trial finds SBRT and radical prostatectomy provide comparable disease control for localized prostate cancer.
Landmark trials to watch
- PSMAddition (NCT04720157): mHSPC. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormo
- STAMPEDE2 (NCT06320067): Advanced, multi-arm. A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
- LIBERTAS (NCT05884398): mHSPC, ADT de-escalation. A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
- PRIMORDIUM (NCT04557059): High-risk biochemical recurrence. A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
- ARASTEP (NCT05794906): Biochemical recurrence, PSMA PET. A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Leve
- PREDICT-RT (NCT04513717): High-risk localized, radiotherapy. Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk S
- GUIDANCE (NCT05050084): Unfavorable intermediate risk, radiotherapy. Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients Wit
- INNOVATE (NCT04134260): Node-positive, radiotherapy. Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
- EvoPAR-Prostate01 (NCT06120491): mHSPC, PARP inhibition. Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
- SunRISe-3 (NCT05714202): BCG-naive high-risk NMIBC. A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NM
- SunRISe-5 (NCT06211764): Recurrent high-risk NMIBC. A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
- KEYNOTE-B15 (NCT04700124): Cisplatin-eligible MIBC, perioperative. Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
- VOLGA (NCT04960709): Cisplatin-ineligible MIBC, perioperative. Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisp
- BRIDGE (NCT05538663): BCG-naive NMIBC, gemcitabine/docetaxel. Intravesical BCG vs GEMDOCE in NMIBC
- INTACT (NCT03775265): Bladder preservation, chemoradiation. Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
- PIVOT-006 (NCT06111235): Intermediate-risk NMIBC. A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
- LITESPARK-022 (NCT05239728): Adjuvant ccRCC. A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
- PROBE (NCT04510597): Cytoreductive nephrectomy, metastatic RCC. Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- RAMPART (NCT03288532): Adjuvant RCC. Renal Adjuvant MultiPle Arm Randomised Trial
- STELLAR-304 (NCT05678673): Non-clear cell RCC. Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
- NORDIC-SUN (NCT03977571): Deferred cytoreductive nephrectomy. Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial
- TIGER (NCT02375204): Relapsed germ cell tumors, salvage chemotherapy. Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
- InPACT (NCT02305654): Advanced penile cancer, nodal management. International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
- EMPASTONE (NCT06653738): Calcium stone prevention, empagliflozin. Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention
- RESTRAIN-SUI (NCT07202884): Stress urinary incontinence with obesity, orforglipron. A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
- TRT-SCI (NCT07742553): Testosterone after spinal cord injury. Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial
- UPRISE (NCT07526545): Early detection, urine test plus MRI. Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial
- G-MAJOR (NCT04396808): Favorable risk, genomic classifier testing. Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer
- APPLY-PSMA (not yet registered): Expected activation spring 2027. APPLY-PSMA
- BLAZE (NCT07187778): Neoadjuvant belzutifan and pembrolizumab, ccRCC. Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
New trials
- Relugolix in Patients With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy. (NCT07927777, Phase 3, Istituto Oncologico Veneto IRCCS)
- PSMA PET/MRI for Predicting and Detecting Prostate Cancer (NCT07924605, Phase 2, University of Wisconsin, Madison)
- Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer (NCT07925268, Phase 2, Rahul Aggarwal)
- ALT-100 Monoclonal Antibody (mAb) in Bone-Predominant Metastatic Androgen Pathway Modulation Resistant (APMR) Prostate Cancer -- The ALTAR-100 Trial (NCT07917390, Phase 1/Phase 2, University of Florida)
- Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer (NCT07914855, Phase 2, National Cancer Institute (NCI))
- MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A) (NCT07908524, Phase 1/Phase 2, Merck Sharp & Dohme LLC)
- A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer (NCT07906717, Phase 3, Janssen Research & Development, LLC)
- Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer (NCT07907653, Phase 2, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University)
- STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma (NCT07902921, Phase 1/Phase 2, National Cancer Institute (NCI))
- Testosterone-Informed De-Escalation in Metastatic Prostate Cancer (TIDE PC) (NCT07904026, Phase 2, University of Nebraska)
- Hypofractionated Radiotherapy With Magnetic Resonance Imaging-Guided Focal Boost and Pelvic Irradiation in High-Risk Prostate Cancer (NCT07900555, Phase 2, Haukeland University Hospital)
- HRT-PC Trial: Hormone Recovery After Treatment for Prostate Cancer Trial. An Open-label Phase II Study of Clomiphene Citrate in Patients With Persistent Hypogonadism After ADT for Treatment of Localized Prostate Cancer (NCT07882862, Phase 2, University of Nebraska)
- A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer Patients (NCT07936422, Phase 2, Centre Leon Berard)
- Sequential Chemotherapy Followed by Ultrahypofractionated Radiotherapy for Muscle-Invasive Bladder Cancer (NCT07914101, Phase 3, Assiut University)
- Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer (NCT07908979, Phase 2, Fox Chase Cancer Center)
- 1 Year Recurrence After Modified en Bloc Resection (ERBT) vs Transurethral Resection (TURBT) for Large Bladder Tumors (NCT07898033, Phase 3, dmitry enikeev)
- A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)] (NCT07890714, Phase 1/Phase 2, Daiichi Sankyo)
- Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma: a Phase 2 Study. (NCT07937553, Phase 2, Kidney Cancer Research Bureau)
- Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors (NCT07933419, Phase 1/Phase 2, Qilu Pharmaceutical Co., Ltd.)
- Lenvatinib And Stereotactic radiothErapy With pembRolizumab in Metastatic Kidney Cancer Patients (NCT07928167, Phase 2, Kidney Cancer Research Bureau)
- Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer (NCT07925333, Phase 2, Beth Israel Deaconess Medical Center)
- Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma (NCT07922915, Phase 2, Sun Yat-sen University)
- Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney Cancer (NCT07922928, Phase 2, Sun Yat-sen University)
- Prospective Study of Cadonilimab With Lenvatinib in Renal Cell Carcinoma (NCT07909265, Phase 2, Cancer Institute and Hospital, Chinese Academy of Medical Sciences)
- A Phase III Randomized Controlled Trial of Serplulimab Plus Fruquintinib as Adjuvant Therapy for High-Risk Non-Clear Cell Renal Cell Carcinoma (NCT07904156, Phase 3, Sun Yat-sen University)
- Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell Carcinoma (NCT07881900, Phase 3, Sun Yat-sen University)
- Sacituzumab Tirumotecan Plus Toripalimab for Advanced Penile Cancer After Platinum Chemotherapy (NCT07907861, Phase 2, Anhui Provincial Hospital)
Today's urology news · Urologic oncology · Subspecialties · Trainee Hub
Loading today's edition…